Hanto, Douglas W <br/><br/>
What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?  [electronic resource] 

 -  Transplantation  Jan 2009 
 - 164-5 p.  digital 
<br/><br/> Publication Type: Comment; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1534-6080 
<br/><br/><label>Standard No.: </label>10.1097/TP.0b013e318192790f  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Calcineurin Inhibitors<br/>Cyclosporine--administration & dosage<br/>Drug Therapy, Combination<br/>Glomerular Filtration Rate--drug effects<br/>Graft Rejection--mortality<br/>Graft Survival--drug effects<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Kidney Transplantation--adverse effects<br/>Randomized Controlled Trials as Topic<br/>Research Design<br/>Sirolimus--administration & dosage<br/>Tacrolimus--administration & dosage<br/>Time Factors<br/>Transplantation, Homologous<br/>Treatment Outcome